ACO2 and prostate cancer: According to Dessai et al., aggressive prostate cancer is facilitated by the increased activity of mitochondrial aconitase (ACO2), which results from the repression of mitochondrial SIRT3 transcription by the androgen receptor and its co-regulator steroid receptor coactivator-2 (SRC-2) [141].